Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Orchestra BioMed Holdings, Inc.HSAQ · Entity 434 | Director | August 03, 2020 | August 10, 2020 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director · CHIEF EXECUTIVE OFFICER | January 31, 2023 | February 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Orchestra BioMed Holdings, Inc.
Report date August 03, 2020 · Filed August 10, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,261 |
Reported balance
Holding disclosure · report date 2020-08-03 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 22,261 |
PTC THERAPEUTICS, INC.
Report date January 31, 2023 · Filed February 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 166,962 |
Reported balance
After 2023-01-31 transaction · row 1
1 source rowRow 1 · 2023-01-31 · Sale · Disposed 2,320 · Balance 166,962 F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 54,903 |
Reported balance
After 2023-01-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-01-31 · Sale · Disposed 301 · Balance 54,903 F2: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 8,250 RSUs from a January 29, 2020 grant of 33,000 RSUs.
F2: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,214 RSUs from a January 29, 2020 grant of 4,855 RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,200 | $60.87 | $73,041.60 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,385 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $60.48 to $61.43 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,090 | $59.56 | $184,037.31 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,585 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $59.12 to $60.05 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,590 | $10.85 | $82,351.50 |
DisclosureSEC source: 0001179110-20-011799 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on November 6, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 8,421 | $33.02 Strike: $33.02 | $278,061.42 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · derivative · entry 28 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 18,529 Underlying: Common Stock · 8,421 shares Expires 2029-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F7 · derivative.exercise_date: This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,065 | $18.01 Strike: $18.01 | $127,240.65 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · derivative · entry 27 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 13,399 Underlying: Common Stock · 7,065 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F6 · derivative.exercise_date: This option was granted on January 3, 2018 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,362 | $11.23 Strike: $11.23 | $26,525.26 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · derivative · entry 26 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 2,363 Underlying: Common Stock · 2,362 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F5 · derivative.exercise_date: This option was granted on January 3, 2017 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,560 | $30.86 Strike: $30.86 | $233,301.60 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · derivative · entry 25 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 7,560 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 2,505 | $18.01 Strike: $18.01 | $45,115.05 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · derivative · entry 24 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 20,464 Underlying: Common Stock · 2,505 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F6 · derivative.exercise_date: This option was granted on January 3, 2018 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,575 | $11.23 Strike: $11.23 | $17,687.25 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · derivative · entry 23 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 4,725 Underlying: Common Stock · 1,575 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F5 · derivative.exercise_date: This option was granted on January 3, 2017 and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 500 | $12.64 Strike: $12.64 | $6,320.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · derivative · entry 22 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 375 Underlying: Common Stock · 500 shares Expires 2026-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F4 · derivative.exercise_date: This option was granted on November 17, 2016 and vests over four years, with 25% of the shares underlying the option vesting on November 17, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on February 17, 2018. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 3,440 | $30.86 Strike: $30.86 | $106,158.40 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · derivative · entry 21 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 7,560 Underlying: Common Stock · 3,440 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 4,900 | $27.05 Strike: $27.05 | $132,545.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · derivative · entry 20 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Underlying: Common Stock · 4,900 shares Expires 2024-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F3 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,421 | $60.00 | $505,260.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 19 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 8,421 | $33.02 | $278,061.42 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 18 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 20,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,065 | $60.00 | $423,900.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 17 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,065 | $18.01 | $127,240.65 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 16 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 19,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,362 | $60.00 | $141,720.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 15 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,362 | $11.23 | $26,525.26 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 14 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 14,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,560 | $60.00 | $453,600.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 13 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 7,560 | $30.86 | $233,301.60 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 12 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 19,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,505 | $60.00 | $150,300.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 11 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,505 | $18.01 | $45,115.05 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 10 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 14,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,575 | $60.00 | $94,500.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 9 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,575 | $11.23 | $17,687.25 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 8 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 13,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 500 | $60.00 | $30,000.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 7 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 500 | $12.64 | $6,320.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 6 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,440 | $60.00 | $206,400.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,440 | $30.86 | $106,158.40 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 15,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,900 | $60.00 | $294,000.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 4,900 | $27.05 | $132,545.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 17,078 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:40 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,037 | $60.00 | $662,220.00 |
DisclosureSEC source: 0001179110-20-010871 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 12,178 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person's spouse on May 11, 2020. F2 · balance_after: Includes 258 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2020. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $10.85 Strike: $10.85 | $542,500.00 |
DisclosureSEC source: 0001179110-20-010780 · edgar.xml · derivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,115 Underlying: Common Stock · 50,000 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F5 · derivative.exercise_date: Currently exercisable. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,813 | $54.79 | $647,281.52 |
DisclosureSEC source: 0001179110-20-010780 · edgar.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $54.42 to $55.06 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,114 | $53.86 | $490,907.38 |
DisclosureSEC source: 0001179110-20-010780 · edgar.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,898 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.42 to $54.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 29,073 | $53.13 | $1,544,764.78 |
DisclosureSEC source: 0001179110-20-010780 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,012 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.42 to $53.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2020 Filed Nov 4, 2020 00:52 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 50,000 | $10.85 | $542,500.00 |
DisclosureSEC source: 0001179110-20-010780 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 26, 2020. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 48,175 | $11.23 Strike: $11.23 | $541,005.25 |
DisclosureSEC source: 0001179110-20-010372 · edgar.xml · derivative · entry 8 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 48,175 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. F8 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,929 | $10.85 Strike: $10.85 | $248,779.65 |
DisclosureSEC source: 0001179110-20-010372 · edgar.xml · derivative · entry 7 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,694 Underlying: Common Stock · 22,929 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020. F7 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 31,681 | $53.62 | $1,698,608.50 |
DisclosureSEC source: 0001179110-20-010372 · edgar.xml · nonDerivative · entry 6 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F4 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.19 to $54.09 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 16,494 | $52.94 | $873,126.38 |
DisclosureSEC source: 0001179110-20-010372 · edgar.xml · nonDerivative · entry 5 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,766 F4 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.19 to $53.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 48,175 | $11.23 | $541,005.25 |
DisclosureSEC source: 0001179110-20-010372 · edgar.xml · nonDerivative · entry 4 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,786 | $53.69 | $632,813.91 |
DisclosureSEC source: 0001179110-20-010372 · edgar.xml · nonDerivative · entry 3 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $53.40 to $54.05 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,143 | $53.01 | $590,712.72 |
DisclosureSEC source: 0001179110-20-010372 · edgar.xml · nonDerivative · entry 2 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,871 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.40 to $53.39 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 20:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 22,929 | $10.85 | $248,779.65 |
DisclosureSEC source: 0001179110-20-010372 · edgar.xml · nonDerivative · entry 1 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right To Buy) · Derivative | 51,825 | $11.23 Strike: $11.23 | $581,994.75 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · derivative · entry 15 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,175 Underlying: Common Stock · 51,825 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. F7 · derivative.exercise_date: This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,511 | $10.85 Strike: $10.85 | $244,244.35 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · derivative · entry 14 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,623 Underlying: Common Stock · 22,511 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020. F6 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,015 | $10.85 Strike: $10.85 | $542,662.75 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · derivative · entry 13 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,115 Underlying: Common Stock · 50,015 shares Expires 2023-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. F6 · derivative.exercise_date: Currently exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 51,825 | $50.14 | $2,598,350.03 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 10 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.62 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 51,825 | $11.23 | $581,994.75 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 9 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 3, 2020. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 01:01 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 22,511 | $50.15 | $1,128,881.63 |
DisclosureSEC source: 0001179110-20-010348 · edgar.xml · nonDerivative · entry 8 Peltz Stuart Walter · CIK 0001578962 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,085 F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on August 11, 2020. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to $50.47 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.